References
- The burden of lung disease [internet]. Sheffield (UK): ers white book; https://www.erswhitebook.org/chapters/the-burden-of-lung-disease/
- Kato A, Schleimer RP. Beyond inflammation: airway epithelial cells are at the interface of innate and adaptive immunity. Curr Opin Immunol. 2007;19(6):711–720.
- Gao W, Li L, Wang Y, et al. Bronchial epithelial cells: the key effector cells in the pathogenesis of chronic obstructive pulmonary disease? Respirology. 2015;20(5):722–729.
- Munford RS. Sensing gram-negative bacterial lipopolysaccharides: a human disease determinant? Infect Immun. 2008;76(2):454–465.
- Rongvaux A. Innate immunity and tolerance toward mitochondria. Mitochondrion. 2018;41:14–20.
- Shao BZ, Xu ZQ, Han BZ, et al. NLRP3 inflammasome and its inhibitors: a review. Front Pharmacol. 2015;6:262.
- Tran HB, Lewis MD, Tan LW, et al. Immunolocalization of NLRP3 inflammasome in normal murine airway epithelium and changes following induction of ovalbumin-induced airway inflammation. J Allergy. 2012;2012:819176.
- Li Y, Wang P, Yang X, et al. SIRT1 inhibits inflammatory response partly through regulation of NLRP3 inflammasome in vascular endothelial cells. Mol Immunol. 2016;77:148–156.
- Hardeland R. Aging, melatonin, and the pro- and anti-inflammatory networks. Int J Mol Sci. 2019;20(5):1223.
- Page CP. Doxofylline: a “novofylline”. Pulm Pharmacol Ther. 2010;23(4):231–234.
- Matera M, Page C, Cazzola M. Doxofylline is not just another theophylline! Int J Chronic Obstr Pulmonary Dis. 2017;12:3487–3493.
- Riffo-Vasquez Y, Man F, Page CP. Doxofylline, a novofylline inhibits lung inflammation induced by lipopolysacharide in the mouse. Pulm Pharmacol Ther. 2014;27(2):170–178.
- Cogo R, Castronuovo A. Effects of oral doxofylline on inflammatory changes and altered cell proliferation in chronic obstructive bronchitis. Eur Rev Med Pharmacol Sci. 2000;4(1–2):15–20.
- Xu GH, Shen J, Sun P, et al. Anti-inflammatory effects of potato extract on a rat model of cigarette smoke-induced chronic obstructive pulmonary disease. Food Nutr Res. 2015;59(1):28879.
- Riffo-Vasquez Y, Venkatasamy R, Page CP. Steroid sparing effects of doxofylline. Pulm Pharmacol Ther. 2018;48:1–4.
- Cazzola M, Calzetta L, Rogliani P, et al. Impact of doxofylline in COPD: a pairwise meta-analysis. Pulm Pharmacol Ther. 2018;51:1–9.
- Folkerts G, Nijkamp FP. Airway epithelium: more than just a barrier! Trends Pharmacol Sci. 1998;19(8):334–341.
- Carnesecchi S, Deffert C, Donati Y, et al. A key role for NOX4 in epithelial cell death during development of lung fibrosis. Antioxid Redox Signal. 2011;15(3):607–619.
- Kleniewska P, Pawliczak R. The participation of oxidative stress in the pathogenesis of bronchial asthma. Biomed Pharmacother. 2017;94:100–108.
- Feng H, Gu J, Gou F, et al. High glucose and lipopolysaccharide prime NLRP3 inflammasome via ROS/TXNIP pathway in mesangial cells. J Diabetes Res. 2016;2016:1–11.
- Cordero MD, Williams MR, Ryffel B. AMP-activated protein kinase regulation of the NLRP3 inflammasome during aging. Trends Endocrinol Metab. 2018;29(1):8–17.
- Li Y, Yang X, He Y, et al. Negative regulation of NLRP3 inflammasome by SIRT1 in vascular endothelial cells. Immunobiology. 2017;222(3):552–561.